China Traditional Chinese Medicine Holdings Co Ltd (HK:0570)
:0570
Want to see HK:0570 full AI Analyst Report?
Top Page
China Traditional Chinese Medicine Holdings Co
(0570)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$1.50
â–¼(-30.56% Downside)
Action:Reiterated
Date:05/02/26
The score is primarily held back by weakening financial performance (profitability falling to a 2025 loss and uneven revenue) and a bearish technical setup (price below key moving averages with negative MACD). A conservative balance sheet, strong recent operating/free cash flow, and a high dividend yield partially offset these risks but are not enough to overcome the earnings and trend deterioration.
Positive Factors
Conservative balance sheet
Improved leverage and low debt into 2024–2025 reduce refinancing and liquidity risk, giving management flexibility to fund capex, R&D or M&A without urgent external financing. This durable strength supports resilience through industry cycles and preserves strategic optionality.
Negative Factors
Earnings deterioration to loss
A structural slide from multi-year profitability to a 2025 net loss weakens return on equity and limits internal funding for growth. Persistent losses impair compounding, reduce strategic reinvestment capacity, and heighten dependence on operational fixes to restore durable shareholder value creation.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Improved leverage and low debt into 2024–2025 reduce refinancing and liquidity risk, giving management flexibility to fund capex, R&D or M&A without urgent external financing. This durable strength supports resilience through industry cycles and preserves strategic optionality.
Read all positive factors
China Traditional Chinese Medicine Holdings Co (0570) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.11B
Dividend Yield3.66%
Average Volume (3M)51.13M
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth-10.68%
EPS Growth-737.07%
CountryHK
Employees16,753
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.07
Shares Outstanding5,035,802,000
10 Day Avg. Volume46,853,920
30 Day Avg. Volume51,130,115
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.64
P/FCF Ratio4.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)HK$14.45B
China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model
Company Description
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of Chinese medicine and pharmaceutical products in the People's Republic of China. The company of...
China Traditional Chinese Medicine Holdings Co Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.74B | 16.51B | 18.12B | 14.30B | 19.05B |
| Gross Profit | 7.09B | 7.86B | 9.27B | 7.20B | 11.83B |
| EBITDA | 1.52B | 1.82B | 2.56B | 2.16B | 3.59B |
| Net Income | -342.07M | 54.07M | 1.29B | 764.49M | 1.93B |
Balance Sheet | |||||
| Total Assets | 32.36B | 35.06B | 37.07B | 35.62B | 36.39B |
| Cash, Cash Equivalents and Short-Term Investments | 5.16B | 5.34B | 3.69B | 3.46B | 4.14B |
| Total Debt | 2.49B | 4.02B | 5.16B | 5.04B | 5.06B |
| Total Liabilities | 8.94B | 11.13B | 13.13B | 12.67B | 13.73B |
| Stockholders Equity | 20.48B | 21.20B | 21.16B | 20.17B | 19.72B |
Cash Flow | |||||
| Free Cash Flow | 1.96B | 2.07B | 680.20M | 565.09M | -81.17M |
| Operating Cash Flow | 2.28B | 2.58B | 1.17B | 1.09B | 796.03M |
| Investing Cash Flow | -172.80M | -379.24M | -477.62M | -374.15M | -536.94M |
| Financing Cash Flow | -2.04B | -1.39B | -584.31M | -557.28M | -724.32M |
China Traditional Chinese Medicine Holdings Co Technical Analysis
Negative
2.16
Price Trends
1.79
Negative
1.95
Negative
2.12
Negative
Market Momentum
-0.05
Positive
34.02
Neutral
20.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0570, the sentiment is Negative. The current price of 2.16 is above the 20-day moving average (MA) of 1.69, above the 50-day MA of 1.79, and above the 200-day MA of 2.12, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.02 is Neutral, neither overbought nor oversold. The STOCH value of 20.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0570.
China Traditional Chinese Medicine Holdings Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$2.54B | 3.07 | 19.22% | 15.97% | -20.14% | -20.91% | |
58 Neutral | HK$9.48B | 11.74 | 5.02% | 4.47% | 5.91% | -40.12% | |
57 Neutral | HK$20.52B | 95.73 | 7.26% | 3.13% | 5.48% | -49.67% | |
56 Neutral | HK$39.39B | 3.39 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.11B | -10.27 | -1.64% | 3.66% | -10.68% | -737.07% | |
46 Neutral | HK$367.75M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% |
* Healthcare Sector Average
HK:0570
China Traditional Chinese Medicine Holdings Co
1.63
-0.44
-21.14%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.21
-0.52
-3.10%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.02
-5.71%
HK:0512
Grand Pharmaceutical Group Limited
5.69
-2.76
-32.66%
HK:6896
Golden Throat Holdings Group Co Ltd
3.40
-1.36
-28.57%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.24
0.45
7.70%
China Traditional Chinese Medicine Holdings Co Corporate Events
China TCM Swings to Loss as Strategic Overhaul Weighs on 2025 Results
Mar 20, 2026
China Traditional Chinese Medicine Holdings reported 2025 revenue of RMB14.74 billion, down 10.7% year on year, with declines across most segments and a sharp 40.2% drop in its Chinese medicinal herbs integration business. The group swung to a net...
China TCM Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 10, 2026
China Traditional Chinese Medicine Holdings has scheduled a board meeting for 20 March 2026 to review and approve the consolidated final results for the year ended 31 December 2025. The board will also consider the declaration of a final dividend,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.